Cytokine profile of conditioned medium from human tumor cell lines after acute and fractionated doses of gamma radiation and its effect on survival of bystander tumor cells

Cytokine

Volumn 61, Issue 1, 2013, Pages 54-62

  Desai, Sejal ^a   Kumar, Amit ^a   Laskar, S ^b   Pandey, B N ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

^b TATA MEMORIAL HOSPITAL   (India)

Author keywords

Acute and fractionated doses of radiation; Bystander effect; Conditioned medium; Cytokines; Human tumor cell lines

Indexed keywords

CD40 LIGAND; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FLT3 LIGAND; FRACTALKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 3; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR BB; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ARTICLE; BREAST ADENOCARCINOMA; BYSTANDER EFFECT; CANCER CELL CULTURE; CANCER SURVIVAL; CELL STRAIN MCF 7; CELL SURVIVAL; CELLULAR DISTRIBUTION; CLONOGENIC ASSAY; COLON CARCINOMA; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE RELEASE; FIBROSARCOMA; GAMMA RADIATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN LOCALIZATION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; UPREGULATION;

BYSTANDER EFFECT; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CULTURE MEDIA, CONDITIONED; CYTOKINES; DOSE FRACTIONATION; GAMMA RAYS; HUMANS; MCF-7 CELLS; NEOPLASMS;

EID: 84869884056     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.08.022     Document Type: Article

References (41)

1. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004, 4:11-22.
2. Purohit A., Newman S.P., Reed M.J. The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res 2002, 4:65-69.
3. Argiles J.M., Busquets S., Lopez-Soriano F.J. Cytokines in the pathogenesis of cancer cachexia. Curr Opin Clin Nutr Metab Care 2003, 6:401-406.
4. Penson R.T., Kronish K., Duan Z., Feller A.J., Stark P., Cook S.E., et al. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 2000, 10:33-41.
5. Mukaida N., Baba T. Chemokines in tumor development and progression. Exp Cell Res. 2012, 318:95-102.
6. Balkwill F.R. Cytokine therapy of cancer. The importance of knowing the context. Eur Cytokine Netw 1994, 5:379-385.
7. Scheibenbogen C., Mohler T., Haefele J., Hunstein W., Keilholz U. Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumour load. Melanoma Res 1995, 5:179-181.
8. Berek J.S., Chung C., Kaldi K., Watson J.M., Knox R.M., Martinez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1991, 164:1038-1042. [discussion 1042-3].
9. Lathers D.M., Young M.R. Increased aberrance of cytokine expression in plasma of patients with more advanced squamous cell carcinoma of the head and neck. Cytokine 2004, 25:220-228.
10. Lev D.C., Onn A., Melinkova V.O., Miller C., Stone V., Ruiz M., et al. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol 2004, 22:2092-2100.
11. Collins T.S., Lee L.F., Ting J.P. Paclitaxel up-regulates interleukin-8 synthesis in human lung carcinoma through an NF-kappaB- and AP-1-dependent mechanism. Cancer Immunol Immunother 2000, 49:78-84.
12. Shi Q., Abbruzzese J.L., Huang S., Fidler I.J., Xiong Q., Xie K. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res 1999, 5:3711-3721.
13. Lau C.K., Yang Z.F., Ho D.W., Ng M.N., Yeoh G.C., Poon R.T., et al. An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells. Clin Cancer Res 2009, 15:3462-3471.
14. Kil W.J., Tofilon P.J., Camphausen K. Post-radiation increase in VEGF enhances glioma cell motility in vitro. Radiat Oncol 2012, 7:25.
15. Munro A.J. Bystander effects and their implications for clinical radiotherapy. J Radiol Prot 2009, 29:A133-A142.
16. Mothersill C.E., Moriarty M.J., Seymour C.B. Radiotherapy and the potential exploitation of bystander effects. Int J Radiat Oncol Biol Phys 2004, 58:575-579.
17. Prise K.M., O'Sullivan J.M. Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer 2009, 9:351-360.
18. Mattei S., Colombo M.P., Melani C., Silvani A., Parmiani G., Herlyn M. Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer 1994, 56:853-857.
19. Moradi M.M., Carson L.F., Weinberg B., Haney A.F., Twiggs L.B., Ramakrishnan S. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer 1993, 72:2433-2440.
20. Burke F., Relf M., Negus R., Balkwill F. A cytokine profile of normal and malignant ovary. Cytokine 1996, 8:578-585.
21. Smith P.C., Hobisch A., Lin D.L., Culig Z., Keller E.T. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 2001, 12:33-40.
22. Ciotti P., Rainero M.L., Nicolo G., Spina B., Garre C., Casabona F., et al. Cytokine expression in human primary and metastatic melanoma cells: analysis in fresh bioptic specimens. Melanoma Res 1995, 5:41-47.
23. Hazelbag S., Fleuren G.J., Baelde J.J., Schuuring E., Kenter G.G., Gorter A. Cytokine profile of cervical cancer cells. Gynecol Oncol 2001, 83:235-243.
24. Merlo A., Juretic A., Zuber M., Filgueira L., Luscher U., Caetano V., et al. Cytokine gene expression in primary brain tumours, metastases and meningiomas suggests specific transcription patterns. Eur J Cancer 1993, 29A:2118-2125.
25. Foussat A., Coulomb-L'Hermine A., Gosling J., Krzysiek R., Durand-Gasselin I., Schall T., et al. Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human. Eur J Immunol 2000, 30:87-97.
26. Boddeke E.W., Meigel I., Frentzel S., Biber K., Renn L.Q., Gebicke-Harter P. Functional expression of the fractalkine (CX3C) receptor and its regulation by lipopolysaccharide in rat microglia. Eur J Pharmacol 1999, 374:309-313.
27. Janson R.W., Hance K.R., Arend W.P. Production of IL-1 receptor antagonist by human in vitro-derived macrophages. Effects of lipopolysaccharide and granulocyte-macrophage colony-stimulating factor. J Immunol 1991, 147:4218-4223.
28. Arend W.P., Smith M.F., Janson R.W., Joslin F.G. IL-1 receptor antagonist and IL-1 beta production in human monocytes are regulated differently. J Immunol 1991, 147:1530-1536.
29. Krzesicki R.F., Hatfield C.A., Bienkowski M.J., McGuire J.C., Winterrowd G.E., Chapman D.L., et al. Regulation of expression of IL-1 receptor antagonist protein in human synovial and dermal fibroblasts. J Immunol 1993, 150:4008-4018.
30. Silvera M.R., Phipps R.P. Synthesis of interleukin-1 receptor antagonist by Thy-1+ and Thy-1- murine lung fibroblast subsets. J Interferon Cytokine Res 1995, 15:63-70.
31. Woods K.V., El-Naggar A., Clayman G.L., Grimm E.A. Variable expression of cytokines in human head and neck squamous cell carcinoma cell lines and consistent expression in surgical specimens. Cancer Res 1998, 58:3132-3141.
32. Chen Z., Malhotra P.S., Thomas G.R., Ondrey F.G., Duffey D.C., Smith C.W., et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 1999, 5:1369-1379.
33. Wang Y.J., Yang M.C., Pan M.H. Dihydrolipoic acid inhibits tetrachlorohydroquinone-induced tumor promotion through prevention of oxidative damage. Food Chem Toxicol 2008, 46:3739-3748.
34. Fratelli M., Gagliardini V., Galli G., Gnocchi P., Ghiara P., Ghezzi P. Autocrine interleukin-1 beta regulates both proliferation and apoptosis in EL4-6.1 thymoma cells. Blood 1995, 85:3532-3537.
35. Dinarello C.A. Interleukin-1 and interleukin-1 antagonism. Blood 1991, 77:1627-1652.
36. Waugh D.J., Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008, 14:6735-6741.
37. Tachibana M., Miyakawa A., Tazaki H., Nakamura K., Kubo A., Hata J., et al. Autocrine growth of transitional cell carcinoma of the bladder induced by granulocyte-colony stimulating factor. Cancer Res 1995, 55:3438-3443.
38. Thacker J.D., Dedhar S., Hogge D.E. The effect of GM-CSF and G-CSF on the growth of human osteosarcoma cells in vitro and in vivo. Int J Cancer 1994, 56:236-243.
39. Old L.J. Tumor necrosis factor (TNF). Science 1985, 230:630-632.
40. Neville L.F., Mathiak G., Bagasra O. The immunobiology of interferon-gamma inducible protein 10kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev 1997, 8:207-219.
41. Shareef M.M., Cui N., Burikhanov R., Gupta S., Satishkumar S., Shajahan S., et al. Role of tumor necrosis factor-alpha and TRAIL in high-dose radiation-induced bystander signaling in lung adenocarcinoma. Cancer Res 2007, 67:11811-11820.